TP53 and lung cancer: SCLC, which accounts for ∼15% of lung cancers, is a highly aggressive and highly vascularized metastatic form of cancer characterized by mutations in TP53 and the transcriptional corepressor RB1, disruption of several signaling networks, and overexpression of MYC, MYCL, and MYCN transcription factors.